Patents Assigned to BIRDIE BIOPHARMACEUTICALS, INC.
  • 2-amino-quinoline derivatives
    Patent number: 11834448
    Abstract: Described herein are 2-amino-quinoline derivatives that are agonists of toll-like receptors 7 and 8 (TLR7/8), pharmaceutical compositions, and methods of use of the compounds and compositions to treat various diseases, such as viral, cancer, and allergic diseases, in need thereof by administering a therapeutically effective amount of a 2-amino-quinoline derivative.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: December 5, 2023
    Assignee: Birdie Biopharmaceuticals, Inc.
    Inventors: Lixin Li, Huiping Guan
  • Compounds and compositions for treating HER2 positive tumors
    Patent number: 11786604
    Abstract: The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of HER2 positive tumors/cancers.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: October 17, 2023
    Assignee: BIRDIE BIOPHARMACEUTICALS, INC.
    Inventor: Lixin Li
  • Anti-EGFR combinations for treating tumors
    Patent number: 11702476
    Abstract: The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: July 18, 2023
    Assignee: BIRDIE BIOPHARMACEUTICALS, INC.
    Inventor: Lixin Li
  • Compounds and compositions for immunotherapy
    Patent number: 11633495
    Abstract: The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of diseases such as cancer.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: April 25, 2023
    Assignee: Birdie Biopharmaceuticals, Inc.
    Inventor: Lixin Li
  • Compounds and compositions for immunotherapy
    Patent number: 11633494
    Abstract: The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of diseases such as cancer.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: April 25, 2023
    Assignee: Birdie Biopharmaceuticals, Inc.
    Inventor: Lixin Li
  • Pharmaceutical compositions
    Patent number: 11517567
    Abstract: The present disclosure relates to new crystal forms of chemical compounds, formulations including, methods of forming, and methods of using same.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: December 6, 2022
    Assignee: Birdie Biopharmaceuticals, Inc.
    Inventor: Lixin Li
  • Anti-PD-L1 combinations for treating tumors
    Patent number: 11279761
    Abstract: The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: March 22, 2022
    Assignee: Birdie Biopharmaceuticals, Inc.
    Inventor: Lixin Li
  • Anti-CD20 combinations for treating tumors
    Patent number: 11220552
    Abstract: The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: January 11, 2022
    Assignee: Birdie Biopharmaceuticals, Inc.
    Inventor: Lixin Li
  • Anti PD-L1 conjugates for treating tumors
    Patent number: 11130812
    Abstract: The present invention discloses anti-PD-L/PD-1 Axis antibody conjugates for targeted immunotherapy, as well as compositions comprising said conjugates. Further, the present invention discloses the use of the conjugates in the treatment of tumor/cancer.
    Type: Grant
    Filed: August 29, 2015
    Date of Patent: September 28, 2021
    Assignee: BIRDIE BIOPHARMACEUTICALS, INC.
    Inventors: Lixin Li, Walter Lau
  • 2-amino-quinoline derivatives
    Patent number: 11053240
    Abstract: Described herein are 2-amino-quinoline derivatives that are agonists of toll-like receptors 7 and 8 (TLR7/8), pharmaceutical compositions, and methods of use of the compounds and compositions to treat various diseases, such as viral, cancer, and allergic diseases, in need thereof by administering a therapeutically effective amount of a 2-amino-quinoline derivative.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: July 6, 2021
    Assignee: Birdie Biopharmaceuticals, Inc.
    Inventors: Lixin Li, Huiping Guan
  • Anti-HER2 combinations for treating tumors
    Patent number: 11046781
    Abstract: A combination which comprises an effective amount of Her2/Neu antagonist and an effective amount of immunotherapeutic that is capable of activating a human plasmacytoid dendritic cell, myeloid dendritic cell, NK cell, or a combination thereof is disclosed.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: June 29, 2021
    Assignee: Birdie Biopharmaceuticals, Inc.
    Inventor: Lixin Li
  • Compounds and compositions for immunotherapy
    Patent number: 10780180
    Abstract: The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of diseases such as cancer.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: September 22, 2020
    Assignee: Birdie Biopharmaceuticals, Inc.
    Inventor: Lixin Li
  • Compounds and compositions for immunotherapy
    Patent number: 10744206
    Abstract: The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of diseases such as cancer.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: August 18, 2020
    Assignee: Birdie Biopharmaceuticals, Inc.
    Inventor: Lixin Li
  • Compounds for targeted immunotherapy
    Patent number: 10660971
    Abstract: Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula TM-Ln-AM, wherein TM is a targeting moiety, AM is an activating moiety that is capable of activating a human dendritic cell, NK cell, or tumor cell, or a combination thereof, Ln is a linker, and n is an integer selected from 0 and 1.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: May 26, 2020
    Assignee: Birdie Biopharmaceuticals, Inc.
    Inventor: Lixin Li
  • Compounds and compositions for treating EGFR expressing tumors
    Patent number: 10548985
    Abstract: Provided are compounds for targeted immunotherapy. The compounds are useful in the treatment of EGFR expressing tumors/cancers. Also provided are compositions comprising the compounds.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: February 4, 2020
    Assignee: Birdie Biopharmaceuticals, Inc.
    Inventor: Lixin Li
  • Compounds for targeted immunotherapy
    Patent number: 10548988
    Abstract: Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula TM-Ln-AM, wherein TM is a targeting moiety, AM is an activating moiety that is capable of activating a human dendritic cell, NK cell, or tumor cell, or a combination thereof, Ln is a linker, and n is an integer selected from 0 and 1.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: February 4, 2020
    Assignee: Birdie Biopharmaceuticals, Inc.
    Inventor: Lixin Li
  • Compounds and compositions for immunotherapy
    Patent number: 10328158
    Abstract: The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of diseases such as cancer.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: June 25, 2019
    Assignee: BIRDIE BIOPHARMACEUTICALS, INC.
    Inventor: Lixin Li
  • Compounds for targeted immunotherapy
    Patent number: 9878052
    Abstract: Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula TM-Ln-AM, wherein TM is a targeting moiety, AM is an activating moiety that is capable of activating a human dendritic cell, NK cell, or tumor cell, or a combination thereof, Ln is a linker, and n is an integer selected from 0 and 1.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: January 30, 2018
    Assignee: BIRDIE BIOPHARMACEUTICALS INC.
    Inventor: Lixin Li
  • Compounds and compositions for immunotherapy
    Patent number: 9827329
    Abstract: Provided are compounds for targeted immunotherapy. The compounds are useful in the treatment of diseases such as cancer. Also provided are compositions comprising the compounds.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: November 28, 2017
    Assignee: BIRDIE BIOPHARMACEUTICALS, INC.
    Inventor: Lixin Li